Status:
RECRUITING
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Lead Sponsor:
Eli Lilly and Company
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 D...
Eligibility Criteria
Inclusion
- Have been diagnosed with T2DM for at least 6 months prior to screening.
- Treated with diet and exercise and stable treatment with metformin with or without 1 additional allowed oral antihyperglycemic medications (OAM), 3 months prior to screening.
- Treatment with metformin will be considered stable if all prescribed total daily doses for this period were ±850 mg from the original prescription for the same participant.
- Allowed OAMs include dipeptidyl peptidase-4 (DPP-IV) inhibitors, sodium-glucose co-transporter-2 (SGLT2) inhibitors, glinides, or sulfonylureas.
- Have a hemoglobin A1c value at screening of
- ≥6.0% (≥ 42 millimole per liter(mmol/L)) and ≤9.5% (≤80 mmol/L) if on metformin only or
- ≥6.0% (≥42 mmol/L) and ≤8.5% (≤69 mmol/L) if on metformin in combination with 1 additional allowed OAM.
- Have a BMI within the range 25.0 kg/m2 and 45.0 kg/m2 kg/m2 (both inclusive).
- Have had a stable body weight that is less than 5% change in body weight for more than 3 months prior to screening.
Exclusion
- Have Type 1 diabetes mellitus.
- Have had more than 1 episode of severe hypoglycemia, as defined by the American Diabetes Association criteria, within 6 months before screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
- Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma requiring hospitalization within the 6 months prior to screening.
- Have impaired renal estimated glomerular filtration rate \<60 mL/min/1.73 m2 calculated by Chronic Kidney Disease-Epidemiology.
- Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.
- Have elevations in
- serum aspartate aminotransferase (AST) \>2.5× upper limit normal (ULN)
- serum alanine aminotransferase (ALT) \>2.5×ULN
- total bilirubin level (TBL) \>1.5×ULN, or
- alkaline phosphatase (ALP) level ≥1.5× ULN.
- Have a known clinically significant gastric emptying abnormality.
Key Trial Info
Start Date :
June 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT06982846
Start Date
June 6 2025
End Date
May 1 2026
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Universität Graz
Graz, Austria, 8010